RTOG 0241 A PHASE I STUDY OF IRINOTECAN AND CISPLATIN IN COMBINATION WITH TWICE DAILY THORACIC RADIOTHERAPY (45 GyOR ONCE DAILY THORACIC RADIOTHERAPY(70 Gy) FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER).

Trial Profile

RTOG 0241 A PHASE I STUDY OF IRINOTECAN AND CISPLATIN IN COMBINATION WITH TWICE DAILY THORACIC RADIOTHERAPY (45 GyOR ONCE DAILY THORACIC RADIOTHERAPY(70 Gy) FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Irinotecan (Primary) ; Cisplatin
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
    • 30 Jun 2009 Additional lead trial investigator Hageboutros A identified as reported by New Jersey Cancer Trial Connect.
    • 04 Nov 2008 Checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top